Walgreens helps gamify adherence through HealthPrize Technologies
NORWALK, Conn. - HealthPrize Technologies on Tuesday announced a collaboration with Walgreens through which the HealthPrize Action Engine patient engagement and medication adherence platform will be offered through Walgreens.com.
"We are continuing to innovate in digital health, enhancing our services and solutions to extend the basic care our pharmacists provide for our patients," said Greg Orr, Walgreens Boots Alliance senior director of digital health. "This platform gives us another opportunity to help improve patient adherence and outcomes, furthering our commitment to being a patient champion and partner of choice."
"We are pleased to be able to offer the HealthPrize platform to select Walgreens patients through this collaboration," stated Tom Kottler, HealthPrize CEO. "This will also give healthcare brands an omni-channel approach to educating and motivating patients to take their medications and achieve improved health outcomes."
The Walgreens program powered by HealthPrize will finish development later this month and will be presented to pharmaceutical sponsors as a way to support patient adherence for prescribed medications. It is planned to be offered to patients filling certain brand-name prescriptions for chronic conditions such as diabetes.
The HealthPrize Action Engine platform utilizes gamification, concepts from behavioral economics and incentives redeemable at Walgreens to motivate patients to engage and learn about their condition and to remain adherent to their medications. Participating patients may be offered weekly condition-related quizzes and surveys, daily health tips and fun facts, leaderboards and competitions, daily medication prompts via email or SMS (at the patient's option), monthly refill reminders and medication adherence scorecards.
The HIPAA-compliant program will also allow participating patients to track any of their other medications filled at Walgreens. It is planned to be ready for implementation with partners in the third quarter for diabetes, with additional conditions such as gastrointestinal, high cholesterol, depression, asthma and COPD, expected in market by the end of the year.